125 related articles for article (PubMed ID: 9860505)
1. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: A comparison with pyronaridine and related antimalarial drugs.
Naisbitt DJ; Williams DP; O'Neill PM; Maggs JL; Willock DJ; Pirmohamed M; Park BK
Chem Res Toxicol; 1998 Dec; 11(12):1586-95. PubMed ID: 9860505
[TBL] [Abstract][Full Text] [Related]
2. Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design.
Naisbitt DJ; Ruscoe JE; Williams D; O'Neill PM; Pirmohamed M; Park BK
J Pharmacol Exp Ther; 1997 Feb; 280(2):884-93. PubMed ID: 9023303
[TBL] [Abstract][Full Text] [Related]
3. Amodiaquine-induced oxidative stress in a hepatocyte inflammation model.
Tafazoli S; O'Brien PJ
Toxicology; 2009 Feb; 256(1-2):101-9. PubMed ID: 19059302
[TBL] [Abstract][Full Text] [Related]
4. Effect of disposition of mannich antimalarial agents on their pharmacology and toxicology.
Ruscoe JE; Tingle MD; O'Neill PM; Ward SA; Park BK
Antimicrob Agents Chemother; 1998 Sep; 42(9):2410-6. PubMed ID: 9736572
[TBL] [Abstract][Full Text] [Related]
5. The bioactivation of amodiaquine by human polymorphonuclear leucocytes in vitro: chemical mechanisms and the effects of fluorine substitution.
Tingle MD; Jewell H; Maggs JL; O'Neill PM; Park BK
Biochem Pharmacol; 1995 Sep; 50(7):1113-9. PubMed ID: 7575670
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis.
Williams DP; Pirmohamed M; Naisbitt DJ; Maggs JL; Park BK
J Pharmacol Exp Ther; 1997 Dec; 283(3):1375-82. PubMed ID: 9400013
[TBL] [Abstract][Full Text] [Related]
7. Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials.
O'Neill PM; Mukhtar A; Stocks PA; Randle LE; Hindley S; Ward SA; Storr RC; Bickley JF; O'Neil IA; Maggs JL; Hughes RH; Winstanley PA; Bray PG; Park BK
J Med Chem; 2003 Nov; 46(23):4933-45. PubMed ID: 14584944
[TBL] [Abstract][Full Text] [Related]
8. Role of hepatic metabolism in the bioactivation and detoxication of amodiaquine.
Jewell H; Maggs JL; Harrison AC; O'Neill PM; Ruscoe JE; Park BK
Xenobiotica; 1995 Feb; 25(2):199-217. PubMed ID: 7618347
[TBL] [Abstract][Full Text] [Related]
9. [Benzo[c][2,7]naphthyridine-5-yl-arylamines-phenol Mannich bases of the amodiaquine-, cycloquine- and pyronaridine-type].
Görlitzer K; Enge C; Jones PG; Jomaa H; Wiesner J
Pharmazie; 2007 Feb; 62(2):89-93. PubMed ID: 17341024
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo metabolism of pyronaridine characterized by low-energy collision-induced dissociation mass spectrometry with electrospray ionization.
Lee J; Son J; Chung SJ; Lee ES; Kim DH
J Mass Spectrom; 2004 Sep; 39(9):1036-43. PubMed ID: 15386754
[TBL] [Abstract][Full Text] [Related]
11. Electrochemical generation of electrophilic drug metabolites: characterization of amodiaquine quinoneimine and cysteinyl conjugates by MS, IR, and NMR.
Jurva U; Holmén A; Grönberg G; Masimirembwa C; Weidolf L
Chem Res Toxicol; 2008 Apr; 21(4):928-35. PubMed ID: 18361508
[TBL] [Abstract][Full Text] [Related]
12. Effects of amodiaquine, chloroquine, and mefloquine on human polymorphonuclear neutrophil function in vitro.
Labro MT; Babin-Chevaye C
Antimicrob Agents Chemother; 1988 Aug; 32(8):1124-30. PubMed ID: 3263835
[TBL] [Abstract][Full Text] [Related]
13. Human glutathione S-transferases- and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: Possible implications for susceptibility to amodiaquine-induced liver toxicity.
Zhang Y; den Braver-Sewradj SP; Vos JC; Vermeulen NPE; Commandeur JNM
Toxicol Lett; 2017 Jun; 275():83-91. PubMed ID: 28478157
[TBL] [Abstract][Full Text] [Related]
14. The mechanism of bioactivation and antigen formation of amodiaquine in the rat.
Harrison AC; Kitteringham NR; Clarke JB; Park BK
Biochem Pharmacol; 1992 Apr; 43(7):1421-30. PubMed ID: 1567466
[TBL] [Abstract][Full Text] [Related]
15. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man.
Maggs JL; Williams D; Pirmohamed M; Park BK
J Pharmacol Exp Ther; 1995 Dec; 275(3):1463-75. PubMed ID: 8531117
[TBL] [Abstract][Full Text] [Related]
16. Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers.
Morris CA; Dueker SR; Lohstroh PN; Wang LQ; Fang XP; Jung D; Lopez-Lazaro L; Baker M; Duparc S; Borghini-Fuhrer I; Pokorny R; Shin JS; Fleckenstein L
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):75-86. PubMed ID: 24590312
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, antimalarial activity, and molecular modeling of tebuquine analogues.
O'Neill PM; Willock DJ; Hawley SR; Bray PG; Storr RC; Ward SA; Park BK
J Med Chem; 1997 Feb; 40(4):437-48. PubMed ID: 9046333
[TBL] [Abstract][Full Text] [Related]
18. A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes.
Gardner I; Zahid N; MacCrimmon D; Uetrecht JP
Mol Pharmacol; 1998 Jun; 53(6):991-8. PubMed ID: 9614200
[TBL] [Abstract][Full Text] [Related]
19. Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis.
Uetrecht JP; Zahid N; Whitfield D
J Pharmacol Exp Ther; 1994 Sep; 270(3):865-72. PubMed ID: 7932198
[TBL] [Abstract][Full Text] [Related]
20. Predicting drug-induced agranulocytosis: characterizing neutrophil-generated metabolites of a model compound, DMP 406, and assessing the relevance of an in vitro apoptosis assay for identifying drugs that may cause agranulocytosis.
Iverson S; Zahid N; Uetrecht JP
Chem Biol Interact; 2002 Nov; 142(1-2):175-99. PubMed ID: 12399162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
